S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
(Ad)
I call it my "Dividend Map", and I'll show you exactly where to find the safest companies that pay the highest yields. (HINT: Texas has 6 of these companies sending huge payouts that average 77%!). I'm willing to send you my Map... but only if you

NASDAQ:RTRX - Retrophin Stock Price, Forecast & News

$16.17
-0.51 (-3.06 %)
(As of 01/20/2020 04:00 PM ET)
Add
Compare
Today's Range
$16.17
Now: $16.17▼
$16.86
50-Day Range
$12.92
MA: $14.35▼
$16.68
52-Week Range
$10.87
Now: $16.17▼
$24.69
Volume190,278 shs
Average Volume391,095 shs
Market Capitalization$694.50 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTRX
Previous Symbol
CUSIPN/A
CIK1438533
Webhttp://www.retrophin.com/
Phone760-260-8600

Debt

Debt-to-Equity Ratio0.82
Current Ratio5.00
Quick Ratio4.94

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$164.25 million
Price / Sales4.23
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.72 per share
Price / Book2.09

Profitability

EPS (Most Recent Fiscal Year)($2.54)
Net Income$-102,680,000.00
Net Margins-71.70%
Return on Equity-43.88%
Return on Assets-18.74%

Miscellaneous

Employees214
Outstanding Shares42,950,000
Market Cap$694.50 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:RTRX Rates by TradingView

(Ad)


A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Retrophin (NASDAQ:RTRX) Frequently Asked Questions

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) issued its quarterly earnings data on Wednesday, October, 30th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.10) by $0.55. The biopharmaceutical company earned $44.37 million during the quarter, compared to analyst estimates of $45.31 million. Retrophin had a negative net margin of 71.70% and a negative return on equity of 43.88%. Retrophin's quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the business posted ($0.68) earnings per share. View Retrophin's Earnings History.

When is Retrophin's next earnings date?

Retrophin is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Retrophin.

What guidance has Retrophin issued on next quarter's earnings?

Retrophin updated its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $175-175 million, compared to the consensus revenue estimate of $173.75 million.

What price target have analysts set for RTRX?

9 brokerages have issued twelve-month price objectives for Retrophin's shares. Their forecasts range from $20.00 to $38.00. On average, they expect Retrophin's share price to reach $29.71 in the next twelve months. This suggests a possible upside of 83.8% from the stock's current price. View Analyst Price Targets for Retrophin.

What is the consensus analysts' recommendation for Retrophin?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Retrophin.

What are Wall Street analysts saying about Retrophin stock?

Here are some recent quotes from research analysts about Retrophin stock:
  • 1. According to Zacks Investment Research, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. " (1/1/2020)
  • 2. Nomura analysts commented, "in PKU Declined; Frees up ~$65mn. RTRX has declined the option for CNSA-001 after strategic review—this has freed up $65mn in capital (and potential dilution), which may be used for acquisition of new drugs/targets. Recall, RTRX paid $10mn for an option to acquire CNSA-001 program for $65mn in 20% cash/80% stock (at $21.40/sh), plus $25mn in milestone payments, on Jan 4, 2018. New BD a EU PKAN Launch. Stock: FSGS DUPLEX 1H21E (was 2H20E); IgAN 1H22E due to slower- than-expected trial enrollment, steps to speed study completion in progress. Fosmet P3 in PKAN Top Line 3Q19 – Approval Likely Even if Primary Endpoint Misses Stat. Sig. Pending P3 data, RTRX intends to submit both NDA and MAA in 2020. Sensitized primary ep (PKAN-ADL) vs. prior studies (UPDRS) highlights FDA flexibility and breadth of potential to detect clinical benefit. Mgmt." (8/8/2019)

Has Retrophin been receiving favorable news coverage?

Media stories about RTRX stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Retrophin earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Retrophin.

Who are some of Retrophin's key competitors?

What other stocks do shareholders of Retrophin own?

Who are Retrophin's key executives?

Retrophin's management team includes the folowing people:
  • Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 60)
  • Mr. Neil F. McFarlane, Chief Operating Officer (Age 46)
  • Dr. William E. Rote, Sr. VP and Head of R&D (Age 56)
  • Dr. Noah L. Rosenberg, Chief Medical Officer (Age 52)
  • Dr. Eric M. Dube Ph.D., Pres, CEO & Director (Age 46)

Who are Retrophin's major shareholders?

Retrophin's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Alpine Global Management LLC (0.03%). Company insiders that own Retrophin stock include Elizabeth E Reed, Eric M Dube, Laura Clague, Neil F Mcfarlane, Noah L Rosenberg, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.

Which major investors are buying Retrophin stock?

RTRX stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. View Insider Buying and Selling for Retrophin.

How do I buy shares of Retrophin?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Retrophin's stock price today?

One share of RTRX stock can currently be purchased for approximately $16.17.

How big of a company is Retrophin?

Retrophin has a market capitalization of $694.50 million and generates $164.25 million in revenue each year. The biopharmaceutical company earns $-102,680,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. Retrophin employs 214 workers across the globe.View Additional Information About Retrophin.

What is Retrophin's official website?

The official website for Retrophin is http://www.retrophin.com/.

How can I contact Retrophin?

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]


MarketBeat Community Rating for Retrophin (NASDAQ RTRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  386 (Vote Outperform)
Underperform Votes:  280 (Vote Underperform)
Total Votes:  666
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: Is a Roth IRA right for you?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel